Special Report: Inside the battle for Genzyme's future
BOSTON (Reuters) – At a recent dinner to honor the achievements of Henri Termeer, chief executive of biotechnology company Genzyme, Ananth Raman broke down as he recalled the moment he learned his 7-month old daughter had Pompe disease, a rare genetic disorder that was damaging her heart. It was 2005 and doctors told him there was no cure. His child, they said, probably had less than five months to live.
Original post here Reuters: Science News
For hot penny stock picks, daily small cap alerts, and stock market news alerts visit http://www.stockorange.com
No Responses to “Special Report: Inside the battle for Genzyme's future”

